Current Status and Future Directions
|
|
- Dustin Hodges
- 5 years ago
- Views:
Transcription
1 Delivery Roundtable Current Status and Future Directions June 25, 2009
2 Agenda RAi and the Role for Delivery Direct RAi Systemic RAi Future Strategies 5
3 RA Interference Synthetic sira dsra Cleavage dicer Strand separation atural Process of RAi Targeted Gene Silencing mra degradation RISC Complementary pairing mra (A) n Cleavage (A) n 6
4 Structure adapted from Klosterman,P. S.; Shah, S. A.; Steitz, T. A Biochemistry (1999), 38, Sense strand Making Drugs ut of siras The Challenge Characteristics M.W 12,000-14,000 Size: 2 turns of helix 40 negative charges ydrophilic ydrated heavily ca. 5.5 nm X 2 nm Biostability base pairs long 2 bp (double) 3 overhangs dsra Seed sequence (residues 2-8) Anti-sense or Guide strand 7
5 Achieving RAi as Therapy Introducing drug-like properties into siras» Potency» Selectivity» Stability Achieving delivery to target tissues/cells» PK/PD/Biodistribution» Cellular uptake 8
6 Delivery of RAi Therapeutics Key driver of success Delivery» PK/PD/Biodistribution» Cellular uptake Major progress achieved Robust in vivo efficacy Delivery Approaches» >25 Targets Conjugates Includes many un-druggable Liposomal Ps» >5 rgans Peptides Includes lung, liver, and CS Antibodies» 6 Species Includes humans 9
7 RAi Delivery Strategies Direct RAi Systemic RAi Respiratory» RSV/Influenza Multiple major diseases» Cystic fibrosis» Metabolic» Asthma/CPD» Viral disease cular» AMD/Retinopathy» Glaucoma CS» europathic pain» Spinal cord injury» untington s disease» Parkinson s disease Topical/Mucosal» Infectious disease» Cancer» Inflammation» Cardiovascular 10
8 RAi Therapeutics pportunity Large umber of Undruggable Targets ew Drug pportunities World of targets Accessible targets for small molecules/antibodies ew targets and disease ral drug space Mab/Protein Drug space on-oral oral SM RAi accessible targets» Undruggable targetst» Potent, selective lead» Rapid; 3-6 month to lead» Cross species active» Multi-targeting t» Allelic specificity» Mab-like PD 11
9 Alnylam Development Pipeline Key Programs Discovery Development Phase I Phase II Phase III RSV Infection Liver Cancers PCSK9/ypercholesterolemia TTR Amyloidosis ID 2009 candidate untington s Disease Alnylam Proprietary Programs Co-development Programs 3 programs in clinical trials in
10 Agenda RAi and the Role for Delivery Direct RAi Systemic RAi Future Strategies 13
11 Direct Delivery in CS Example: Cy3-tt sira Distribution tion After Intrastriatal Infusion Cortex Striatum Thalamus Substantia igra 14 DSA (2008)
12 orm malized CP/MBP (% PBS) Silencing of Rat CPase Infusion Duration: ~3 d Infusion rate: 10 µl/hr *** ** PBS AD (mg/ml) Direct Delivery in CS Example: An ligodendrocyte Gene Piece 0 Piece 1 *** p< ** p<0.01 vs PBS Two way AVA RA adaptor sira cleavage site GR5 1118/1119 RAi-Mediated Cleavage of CPase in Rats GSP RTGSP 3 ~299bp Predicted product Step I. Ligation of adaptor Step II. cda Synthesis Step III. PCR PBS sicp PBS sicp Relative CPase/MB BP mra (%) Silencing of Primate CPase 500 Injection Site Adjacent Site Infusion Duration: 7 days Infusion Rate: 20 µl/hr Control Animal #1 Animal # nt Regular PCR TD PCR Verified by cloning and sequencing of amplified products (18/20 clones) Querbes et al., ligonucleotides (2008) 15
13 Direct Delivery in CS Therapeutic Silencing of untingtin Strong pre-clinical data support advancement toward clinic RAi therapeutic targeting huntingtin corrects disease in animal model» Silencing of huntingtin gene» Decreased disease pathology and behavioral changes Mean # of foot slips Behavior Improvement in Disease Model 8 ormal mice 7 Control sira TT sira * p 0.01 * Mean number neuropil aggregates/ μm Improved istopathology Luc TT sira * * 0 ormal Pre-Disease Induction 7 Days Post-Disease Induction 0 Group 1 Group 2 16 PAS (2007) 104,
14 FIS Staining in Lung 4 ours after Single 10 mg/kg Dry Powder or Liquid sira Installation Luc sira DP, 4 rs, x10 o Treatment, x10 eg Ctrl sira DP, 4 rs, x10 Luc sira D5W, 4 rs, x10 17
15 Direct Delivery in Lung Example: Anti-viral Activity of RSV siras U/g lung Log10 PF mg/kg 2 mg/kg 4 mg/kg 1 LLD 0 P1 P2 P3 AL-RSV01 2 L1 L2 L3 P4 P4-MM Pgene gene Lgene sira i.n. (25-100ug) 4 hrs Virus (RSV/A 2 ) i.n. (10 6 pfu) 4 days Viral Titer in Lung RSV Symposium, Aug
16 AL-RSV01 Phase II GEMII Study uman PC for RAi Therapeutics AL-RSV01 shows statistically significant reduction in RSV infection Randomized, double-blind, placebo-controlled study (n=88) ~40% Relative reduction in infection rate (P<0.01) 01) ~95% Increase in number of uninfected subjects (P<0.01) % Infec cted Placebo Plaque Assay AL-RSV01 ~40% Reduction o. of Unin nfected P<0.01 Plaque Assay ~95% Increase P= Study Day 0 Placebo AL-RSV01 Int l Symp Res Vir Infect, Feb
17 sira Conjugates Enhance Delivery 3 5 P E.g., Cholesterol Promotes cellular uptake» Direct cell permeation ature (2004) 432, % Gen ne expression RAi Activity in vitro without transfection reagent Unmodified Cholesterol conjugated sira dose (nm) 20
18 Direct Delivery to Mucosal Tissue Intravaginal Application of Chol-siRA against ectin 1 21 Cell ost Microbe (2009) 5,84-94
19 Agenda RAi and the Role for Delivery Direct RAi Systemic RAi Future Strategies 22
20 Systemic RAi Parenteral administration increases access to multiple major diseases» Metabolic» Viral disease» Cancer» Inflammation» Cardiovascular Validated Systemic RAi approaches» Conjugates» Liposomal nanoparticles Multiple approaches» Polymers» Small molecules» Peptides» Antibodies 23
21 Chol-siRAs Silence apob in Liver and Jejunum Saline treatme ent group Liver Jejunum % ApoB mra conte ent relative to saline Chol-luc- Chol-MM unconjugated apob-1 * * Chol-apoB-1 * * Chol-apoB-2 * P< compared to saline control animals ature (2004) 432,
22 Lipophilic Conjugates SAR for Gene Silencing In Vivo 5' 3' P Y Y = or S L Cholesterol (C 27 ) * P<0.05 ** P<0.005 Lithocholic-oleyl (C 43 ) Rel. apob mra (%) * * 60 ** ** 40 Docosanoyl (C 22 ) Stearoyl (C 18 ) Lauroyl (C 12 ) 20 Myristoyl (C 14 ) 0 PBS C27 MM C27 C18 C22 C43 C12 C14 C16 Palmitoyl (C 16 ) Linoleoyl (C 18, two C=C bond) Wolfrum et al., at. Biotech. Sep
23 Biodistribution of Chol-siRAs is Lipoprotein-Mediated Chol-siRAs bind to circulating lipoproteins and traffic to tissue in a receptor-mediated fashion ature Biotech (2007). 25:
24 Lipoprotein-mediated uptake of chol-siras into tissues of Ldlr / and wildtype mice Stoffel, Keystone March
25 Liposomal anoparticles for Systemic RAi Multi-component lipid formulation» Cationic lipid» Fusogenic lipid» PEG lipid» Cholesterol ighly efficient for liver delivery» epatocyte-specific gene silencing achieved Low surface charge Small uniform size particle < 100 nm 28
26 Liposomal sira Delivery to Liver Mouse 100 Clearance from Plasma Detection of Cy3-siRA in Liver % Injected D ose % Injecte ed Dose Time 100 Detection in Tissues mins Composite Control o 10 mg/kg g 3 mg/kg g 1 mg/kg g Liver Lungs Kidney eart Femur Thymus Small intestine Muscle Fat 29
27 Relative Live er FVII mra Dose-Dependent Silencing of Factor VII Liver Factor VII mra Relative FV VII Protein Plasma Factor VII Protein Rat PBS sicont 10mg/kg sifvii 10mg/kg sifvii 5mg/kg sifvii 2.5mg/kg sifvii 1.25mg/kg 0.0 PBS sicont 10mg/kg sifvii 10mg/kg sifvii 5mg/kg sifvii 2.5mg/kg sifvii 1.25mg/kg Prothrombin Time Durability Prothro ombin Time (s) Relative FVII protein *** * 5 0 PBS sicont 10mg/kg sifvii 10mg/kg sifvii 5mg/kg sifvii 2.5mg/kg sifvii 1.25mg/kg *** *** ** *** sicont sifvii Time (d) ature Biotechnology (2008) 26,
28 Repeat dosing over 3 months highly effective Repeat Silencing of Factor VII Comparable potency and durability of silencing with repeat dosing o evidence for tachyphylaxis y a or immunogenicity sicont sifvii Rat n FVII protei Relative Time (days) Dose 1 Dose 2 Dose 3 Molecular Therapy (2009) 17,
29 % Co ontrol 32 Silencing apob on-uman Primate Efficacy in monkeys with Systemic RAi after single IV injection Effects are rapid, potent, dose-dependent and durable RAi effects are specific and lead to measurable therapeutic benefit RAi mechanism proven in vivo * P <.05 ** 31.7 ** ** P < ** mra Protein 1mg/kg 2.5 mg/kg 1 mg/kg 2.5 mg/kg ature (2006) 441, ** day 11 day * % Control * P <.05 ** P <.005 >65% Inhibition * 34.1 >85% Inhibition ** Cholesterol LDL DL Day 11 Post-Dose (2.5 mg/kg)
30 Alnylam Systemic Programs AL-PCS, AL-TTR, AL-VSP AL-PCS to treat hypercholesterolemia Targets PCSK9 ID candidate for 2009 AL-TTR to treat TTR amyloidosis Targets liver expressed TTR ID candidate for 2009 AL-VSP to treat liver cancer Target two key genes» KSP critical for cell division» VEGF critical for angiogenesis Phase I KSP/ VEGF PCS TTR 33
31 RAi to treat liver cancers Prevalent solid tumor and common site of metastatic disease» ~700,000/yr Incidence of CC worldwide» ~500,000/yr Patients with liver metastasis AL-VSP is dual-target product» Targeting 2 pathways increases potential therapeutic impact Proliferation: Kinesin Spindle Protein (KSP) Angiogenesis: VEGF» Liposomal nanoparticle formulation With Tekmira Pharmaceuticals AL-VSP in clinical development» Phase I liver cancer patient study Liver Cancer Program AL-VSP 34
32 RAi-Mediated Cell Cycle Arrest Murine Liver Cancer Model rthotopic tumor model with intrahepatic ep3b seeding in SCID mice Single IV bolus injection of AL-VSP or control sira Mitotic arrest (monoasters) clearly detected in VSP-treated animals KSP and VEGF target mras cleaved in tumors confirming RAi mechanism Control sira hksp mra hvegf mra AL-VSP RA adapter GR5 hksp mra 3 cleavage product hksp mra 3 cleavage product Rev3 Rev2 cda RA adapter GR5 hvegf mra 3 cleavage product hvegf mra 3 cleavage product Rev4 Rev3 cda PCR product 380 nt VSP mg/kg PCR product 210 nt VSP mg/kg Keystone: RAi, Feb 2009
33 AL-VSP Anti-Tumor Activity Murine Liver Cancer Model rthotopic tumor model with intrahepatic ep3b seeding in SCID mice AL-VSP demonstrates clear anti-tumor activity compared with controls Control sira, n=6 AL-VSP, n=7 36 Keystone: RAi, Feb 2009
34 AL-VSP Anti-Tumor Activity Comparative Efficacy vs. Sorafenib rthotopic tumor model with intrahepatic ep3b seeding in SCID mice Significant survival benefit of AL-VSP treatment vs. controls Superior survival advantage of AL-VSP vs. sorafenib treatment Control Sorafenib Soraf/Control Soraf+AL-VSP AL-VSP (%) Survival log-rank Control 20 Soraf S Soraf Soraf/Cntrl S S Soraf/Cntrl VSP p=0.002 p=0.012 p=0.020 VSP Soraf/VSP p= p=0.003 p=0.025 S Keystone: RAi, Feb 2009
35 PCSK9/ypercholesterolemia Program AL-PCS RAi to treat hypercholesterolemia Significant unmet medical need» >500,000 Patients with severe hypercholesterolemia Inadequately managed by statins ti and other drugs PCSK9 is regulator of LDL metabolism» Controls expression of LDL receptor» Validated in human genetics Attractive opportunity for Systemic RAi» PCSK9 expressed in liver» Early clinical markers of activity possible Collaboration with UT Southwestern» orton, obbs, Brown, and Goldstein 38
36 lative to pre-d dose rel RAi Silencing of PCSK9 Protein and LDLc Efficacy of PCSK9 silencing in non-human primates on-uman Primates PCSK9 plasma levels reduced by up to 70% of pre-dose levels Rapid reductions in LDL cholesterol l levels l by 40-60% Durable effects after single injection PCSK9 protein Day 4 Day 7 Day 14 Day 21 * p 0.05 PBS Control PCSK9 sira sira * rel ative to Pre-d dose LDL Cholesterol Day 4 Day 7 Day 14 Day 21 * p 0.05 * * * PBS Control PCSK9 sira sira 39 PAS (2008) 105,
37 RAi to treat significant orphan disease Transthyretin (TTR) Amyloidosis» Caused by mutation in TTR gene» Amyloid deposits in nerves and heart Familial Amyloid Polyneuropathy (FAP) Familial Amyloid Cardiomyopathy (FAC)» ~10, patients WW with FAP Clinical pathology» Typical onset ~30-50 yr» Fatal within 5-15 years» Severe pain/loss of autonomic nervous function TTR is well-validated target» uman and mouse genetics o pathology in knock-out mouse» Produced d almost exclusively l in liver (95%) Liver transplant current standard of care TTR Amyloidosis Program AL-TTR 40
38 RAi Silencing of Mutant and Wild-Type TTR Mouse and on-uman Primate Efficacy in transgenic mouse model and non-human primates Reduced mutant t V30M-TTR plasma a levels e and liver mra >90% in transgenic mice Reduced liver TTR mra levels ~80% in non-human primates httr transgenic mouse* 1mg/kg 3mg/kg 6mg/kg on-human primate** 0.3 mg/kg g 1 mg/kg g 3 mg/kg g TTR/GAPD D TTR/GAP PBS Control TTR sira sira 0.0 Control TTR sira sira 41 Keystone: RAi, Feb 2009 *Lipidoid formulation, w/ MIT; **SALP formulation, Tekmira
39 Agenda RAi and the Role for Delivery Direct RAi Systemic RAi Future Strategies 42
40 Future Strategies ptimizing LPs» ew formulations of lipids» ew lipids» Tailoring PK/PD and biodistribution Targeting ligands» ew conjugates» Targeted liposomes ssrai» ew physical properties 43
41 Liposome Formulation Development Progress Efficacy Improvement ver Time r VII % Residual Facto LP D LP C LP B LP01 LP A ED FVII sira Dose (mg/kg) Int l Symp Athero, June
42 Lipidoid Library for ovel anoparticles Library Components Alnylam-MIT lam Collaboration In Vitro Screen Q10 Q12 Q13 Q14 Q TEST Synthetic Scheme R 1 R ΔT MeI Me R 2 R 2 R 1 R2 91 R 1 R R R 1 ΔT R 2 1 R 1 R 1 ature Biotechnology (2008) 26,
43 Factors That Impact LP Pharmacology Stability of PEGylation Particle Size Molecular Therapy (2009) 17,
44 PK/Biodistribution of LPs Can Be Modified JCI (2009) 119,
45 PBS=1 relative to Initial Dosing and Lower Maintenance Dose PCSK9/GAPD Cholesterol Multiple Injections LP formulated PCS A2 (mg/kg) 0.6 otal Cholesterol elative to PBS=1 To Re PBS 3mg/kg bolus+ PBS once a week 3mg/kg bolus mg/kg per week days post initial bolus Initial 3mg/kg bolus Maintenance: 1 x wk Rats were bled one day prior to repeated dosing Int l Sym of Athero, June
46 Targeted Delivery The use of targeting ligands may substantially develop delivery solutions to increase» Efficiency» Access to other tissues Applicable to both conjugate and LP strategies Targeting approaches» Small molecules» Peptides» Monoclonal antibodies 49
47 Alnylam Delivery Strategy Two key systemic delivery strategies at Alnylam» Lipid nanoparticles Including targeting with ligands» Conjugates Including targeting with ligands A third delivery strategy» Single stranded siras An early an alternate approach to delivery of siras Agreement with Isis 50
48 Single Stranded and Duplex si-ras Physiochemical Properties Single-stranded sira MW ~ formal negative charges Flexible with ~ 1 nm width ydrophobic surfaces accessible for protein interactions» Aromatic bases (green) are exposed Double-stranded sira MW ~13,000 Two molecules (one strand pink) 40 formal negative charges Rigid with ~ 2 nm diameter Very little exposed hydrophobic surface» Aromatic bases (green) are paired and buried in duplex These different physical/chemical properties will likely result in marked differences in pharmacokinetic profiles 51
49 Importance of Mechanistic Insights RISC 52
50 Multiple Ways into the Cell Collaboration with Merino Zerial 53 Keystone: RAi, Feb 2009
51 RAi Delivery Alnylam has broad and long-term commitment to improving and expanding delivery technology Continue development of direct and systemic approaches» Many technologies under evaluation Direct RAi Systemic RAi» ew Liposomes and lipidoids» ew conjugates including peptides and antibodies» Single strand sira Basic research» Marino Zerial Alnylam approached pro-actively by academics and companies» >25 evaluations ongoing with external groups at any one time 54
52 visit our newly launched
PCSK9 RNAi Therapeutics. Kevin FitzGerald
PCSK9 RNAi Therapeutics Kevin FitzGerald Presenter Disclosure Information PSCK9 RNAi Therapeutics The following relationships exist related to this presentation:» Kevin Fitzgerald and Alnylam team members:
More informationPhase 1 Trial of ALN-VSP in Cancers Involving the Liver. Annual Meeting of the Controlled Release Society August 2, 2011
Phase 1 Trial of ALN-VSP in Cancers Involving the Liver Annual Meeting of the Controlled Release Society August 2, 2011 Agenda ALN-VSP: Background Phase 1 Trial Study Design Safety Data Tumor Response
More informationAlnylam RNAi Roundtable. May 13, 2011
Alnylam RNAi Roundtable May 13, 2011 Agenda & Introductions Welcome Cynthia Clayton» Senior Director, Investor Relations and Corporate Communications Program Overview Akshay Vaishnaw, M.D., Ph.D. (Moderator)»
More informationAsiaTIDES 2012: Formulation and Delivery of Peptides and Oligonucleotides Strategies for Delivery of RNAi Therapeutics. March 1, 2012 Akin Akinc, PhD
AsiaTIDES 2012: Formulation and Delivery of Peptides and Oligonucleotides Strategies for Delivery of RNAi Therapeutics March 1, 2012 Akin Akinc, PhD Lead Selection Alnylam RNAi Product Platform Turning
More informationSupplementary Information: Figures 1-6 and Table 1 RNAi-Mediated Gene Silencing in Non-Human Primate Zimmermann, T.S. et al.
Supplementary Information: Figures 1-6 and Table 1 RNAi-Mediated Gene Silencing in Non-Human Primate Zimmermann, T.S. et al. a. 12 14 Relative apob mrna (%) 8 6 4 2 Relative apob mrna (%) 12 8 6 4 2 5
More informationProgress in the Treatment of Cardiac Amyloidosis
Progress in the Treatment of Cardiac Amyloidosis Jignesh Patel MD PhD FACC FRCP Director, Cardiac Amyloid Program Medical Director, Heart Transplant Program Clinical Professor Cedars-Sinai Heart Institute,
More informationVarun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1
Population Pharmacokinetic (PK) / Pharmacodynamic (PD) Model of Serum Transthyretin (TTR) Following Patisiran Administration in Healthy Volunteers and Patients with Hereditary TTR-Mediated (hattr) Amyloidosis
More informationreversing familial amyloid polyneuropathy naturally the raw vegan plant based detoxification regeneration workbook for healing patients volume 2
DOWNLOAD OR READ : REVERSING FAMILIAL AMYLOID POLYNEUROPATHY NATURALLY THE RAW VEGAN PLANT BASED DETOXIFICATION REGENERATION WORKBOOK FOR HEALING PATIENTS VOLUME 2 PDF EBOOK EPUB MOBI Page 1 Page 2 healing
More informationXiaoping (Amy) Zhang, Varun Goel, Husain Attarwala, and Gabriel Robbie. Alnylam Pharmaceuticals, Cambridge, USA
Patisiran Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Relationship in Patients with Hereditary Transthyretin-Mediated (hattr) Amyloidosis Xiaoping (Amy) Zhang, Varun Goel,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: patisiran_onpattro 11/2018 n/a 5/2019 2/2019 Description of Procedure or Service is a double-stranded small
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationR&D Webinar: Product Pipeline Update
R&D Webinar: Product Pipeline Update Dr. Mark Murray, President & CEO Dr. Mark Kowalski, Chief Medical Officer Dr. Ian MacLachlan, Chief Scientific Officer Ian Mortimer, Executive Vice President Bruce
More informationALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald, PhD Co-authors: Amy Simon 1, Suellen White 1,
More informationCorporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO
NASDAQ: DRNA Corporate Overview H.C. Wainwright & Co. Global Life Sciences Conference April 10, 2018 Douglas M. Fambrough, CEO Jack Green, CFO Forward looking statements This information may contain projections
More informationImmunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) Les Tari, PhD VP Discovery
Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) Les Tari, PhD VP Discovery Cidara s pipeline addresses multiple unmet needs Program Indication Discovery IND- enable Ph 1 Ph 2 Ph 3 REZAFUNGIN IV
More informationMicroRNA in Cancer Karen Dybkær 2013
MicroRNA in Cancer Karen Dybkær RNA Ribonucleic acid Types -Coding: messenger RNA (mrna) coding for proteins -Non-coding regulating protein formation Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL
ACTIVITY OF BRINCIDOFOVIR (BCV) AGAINST MURINE POLYOMAVIRUS (MUPYV) IN A MOUSE INFECTION MODEL Kidney Week 2018 Poster # SA-PO642 BRINCIDOFOVIR(BCV) DEMONSTRATES ANTIVIRAL ACTIVITY AGAINST MURINE POLYOMAVIRUS
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationEducation Brochure. Hereditary ATTR amyloidosis A closer look at an inherited condition
Education Brochure Hereditary ATTR amyloidosis A closer look at an inherited condition What is hereditary ATTR (hattr) amyloidosis? hattr amyloidosis is caused by a gene change (mutation) that affects
More informationINTERNAL MEDICINE - PEDIATRICS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 2 INTERNAL MEDICINE - PEDIATRICS UPDATES NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY A.L. Strat
More informationALN-HBV. Laura Sepp-Lorenzino November 11, Alnylam Pharmaceuticals, Inc.
ALN-HBV Laura Sepp-Lorenzino November 11, 2016 2016 Alnylam Pharmaceuticals, Inc. 1 N-Acetyl Galactosamine (GalNAc) sirna Conjugates Subcutaneous Investigational RNAi Therapeutics 5 -sense 5 -AS ASGPR
More informationProthena Corporation plc Overview
November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationOncology Program. Chlorotoxin Technology Platform. Corporate Partnering Opportunities
TransMolecular, Inc. A Neuroscience Biotechnology Company Oncology Program Chlorotoxin Technology Platform Corporate Partnering Opportunities Background TransMolecular, Inc. (TMI) is a neuroscience biotechnology
More informationand Results of Lung Transplant Study with ALN-RSV01 July 30, 2009
ALN-RSV Program Overview and Results of Lung Transplant Study with ALN-RSV01 July 30, 2009 Alnylam Forward Looking Statements This presentation contains forward-looking statements. There are a number of
More informationInclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia
ORION-1 Trial Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHA St Michael s Hospital, Toronto 1 Presented on behalf
More informationLiposome Mediated Delivery of sirna to Hepatic Stellate Cells Alfica Sehgal, Mohammad Zafari, Boris Klebanov, Greg Hinkle, Satya Kuchimanchi, Sarfraz
Liposome Mediated Delivery of sirn to Hepatic Stellate ells lfica Sehgal, Mohammad Zafari, oris Klebanov, Greg Hinkle, Satya Kuchimanchi, Sarfraz Shaikh, Martin Maier, Jonathan O Shea, Lauren Speciner,
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationSpherical Nucleic Acids For Advanced Wound Healing Applications Chad A. Mirkin
Spherical Nucleic Acids For Advanced Wound Healing Applications Chad A. Mirkin Departments of Chemistry, Infectious Disease, Materials Science & Engineering, Chemical & Biological Engineering, and Biomedical
More informationDevelopment of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer
Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer Khursheed Anwer, Ph.D. Executive Vice President and CSO Molecular Medicine
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationElectron micrograph of phosphotungstanic acid-stained exosomes derived from murine
1 SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURES Supplementary Figure 1. Physical properties of murine DC-derived exosomes. a, Electron micrograph of phosphotungstanic acid-stained exosomes derived from
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationRXi Pharmaceuticals. sd-rxrna Demonstrate Robust Efficacy in the Eye. Dr. Geert Cauwenbergh President & CEO OTCQX: RXII. Next Generation in RNAi
RXi Pharmaceuticals sd-rxrna Demonstrate Robust Efficacy in the Eye Next Generation in RNAi Dr. Geert Cauwenbergh President & CEO OTCQX: RXII 2 Forward Looking Statements This presentation contains forward-looking
More informationTKM-HBV RNAi Therapeutic for Chronic Hepatitis B Infection
TKM-HBV RNAi Therapeutic for Chronic Hepatitis B Infection Amy Lee, Arbutus Biopharma DIA/FDA Oligonucleotide-Based Therapeutics Conference September 9 Washington, DC Disclaimer The views and opinions
More informationOCCUPATIONAL HEALTH CONSIDERATIONS FOR WORK WITH VIRAL VECTORS
OCCUPATIONAL HEALTH CONSIDERATIONS FOR WORK WITH VIRAL VECTORS GARY R. FUJIMOTO, M.D. PALO ALTO MEDICAL FOUNDATION ADJUNCT ASSOCIATE CLINICAL PROFESSOR OF MEDICINE DIVISION OF INFECTIOUS DISEASES AND GEOGRAPHIC
More informationSupplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
More informationStabilization of Live Attenuated Virus Vaccines. Dr. Reinhard Vehring MedImmune Vaccines, Inc. 319 North Bernado Avenue Mountain View, CA 94043
Stabilization of Live Attenuated Virus Vaccines Dr. Reinhard Vehring MedImmune Vaccines, Inc. 319 North Bernado Avenue Mountain View, CA 94043 Outline Model System Stabilization Strategy Processing Options
More informationSupplementary Material
Supplementary Material Summary: The supplementary information includes 1 table (Table S1) and 4 figures (Figure S1 to S4). Supplementary Figure Legends Figure S1 RTL-bearing nude mouse model. (A) Tumor
More informationStacey Melquist #AHA16
Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein(a) Monday, November 14, 2016
More informationSpecific Targeting and Delivery of Therapeutics to Cancer Cells Based on the Tumor Microenvironment
Specific Targeting and Delivery of Therapeutics to Cancer Cells Based on the Tumor Microenvironment Damien Thévenin Department of Chemistry Bioscience in the 21st century (Sep. 14, 218) Anticancer Drugs
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationSubject: Patisiran (Onpattro )
09-J3000-16 Original Effective Date: 12/15/18 Reviewed: 11/14/2018 Revised: 01/01/19 Subject: Patisiran (Onpattro ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF
More informationFamilial Hypercholesterolemia
Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:
More informationJohn Bell Centre for Innovative Cancer Therapeutics
Enhancing Oncolytic Virus Activity by Engineering of Artificial micrornas John Bell Centre for Innovative Cancer Therapeutics Affiliated with Affilié à 1 Oncolytic Viruses: A Therapy for Metastatic Cancers?
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationMR04A3 An isoindoline derivative, New Sedative/Anesthetic Agent
MR04A3 An isoindoline derivative, ew Sedative/Anesthetic Agent ovember 2009 1 Introduction Sedatives are widely used in: Settings providing stressful and painful procedures Gastroenterology (colonoscopy
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationMolecular Imaging of CXCR4 Receptors
Molecular Imaging of CXCR4 Receptors.J. Wester uklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar and Institut für Radiochemie TUM Campus Garching Importance of CXCR4 and CXCL12 ypoxic
More informationSupporting Information. Maximizing the Supported Bilayer Phenomenon: LCP Liposomes Comprised Exclusively
S-1 Supporting Information Maximizing the Supported Bilayer Phenomenon: LCP Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery Matthew T. Haynes and
More informationCANCER THERAPEUTICS: A NOVEL APPROACH
CANCER THERAPEUTICS: A NOVEL APPROACH Mary Dwyer, Ph.D. HBRI and ChemRegen, Inc. SCDMDG Meeting October 23, 212 Outline Introduction Hit, HBRI1: identification & characterization Leads, HBRI2 & HBRI3:
More informationQuality, safety and standards for poliomyelitis vaccines
Quality, safety and standards for poliomyelitis vaccines 7 th WHO/UNICEF consultation Geneva, 30 October 2008 Jackie Fournier-Caruana, WHO/QSS 1 Expert Committee on Biological Standardization The ECBS
More informationPK and PD Properties of Antisense Oligonucleotides: Bridging Nonclinical to Clinical
PK and PD Properties of Antisense ligonucleotides: Bridging Nonclinical to Clinical Rosie Z. Yu, Ph.D. Pharmacokinetics & Clinical Pharmacology Isis Pharmaceuticals, Inc. Carlsbad, CA USA 2 Antisense Mechanism
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationVasoRx: Atherosclerotic Plaque Regression
VasoRx: Atherosclerotic Plaque Regression A progressive disease characterized by plaque build-up in large arteries, leading to heart attacks, stroke, and peripheral vascular disease. Induced by a combination
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationNovel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27
Novel Reduction of PCSK9 Expression: Mechanistic Insights into the Anti-Atherosclerotic & Hypolipidemic Effects of Heat Shock Protein 27 Ed O Brien, Jean-Claude Bakala-N Goma, Chunhua Shi Cumming School
More informationTTR-FAP: Diagnosis and treatment Zürich June 19,2014. Ole B Suhr Umeå University and University Hospital Department of Medicine Umeå Sweden
TTR-FAP: Diagnosis and treatment Zürich June 19,2014 Ole B Suhr Umeå University and University Hospital Department of Medicine Umeå Sweden Diagnosis of ATTR amyloidosis Clinical symptoms of ATTR- amyloidosis
More informationParadim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie
Paradim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie Prof. G.Kees Hovingh, MD PhD MBA Dept. Vascular Medicine Academic Medical Center Amsterdam, the Netherlands Risk and profit
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationBeta Amyloid Peptides
Beta Amyloid Peptides The Most Comprehensive Collection for Alzheimer s Disease Academic Services Pharmaceutical Services Beta Amyloid Peptides The Most Comprehensive Collection for Alzheimer s Disease
More informationSupplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved
1 Supplemental Figure Legends Supplemental Figure 1 ELISA scheme to measure plasma total, mature and furin-cleaved PCSK9 concentrations. 4 Plasma mature and furin-cleaved PCSK9s were measured by a sandwich
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationIdentification of Oral Bioavailable, Type2 Inhibitors of Discoidin Domain-containing Receptor 1/2 (DDR1/DDR2) using Back-to-Front X-Ray FBDD
Identification of ral Bioavailable, Type2 Inhibitors of Discoidin Domain-containing Receptor 1/2 (DDR1/DDR2) using Back-to-Front X-Ray FBDD Emiliano Tamanini 26 th Symposium on Medicinal Chemistry in Eastern
More informationSupplemental Figure 1
1 Supplemental Figure 1 Effects of DATE shortening on HGF promoter activity. The HGF promoter region (-1037 to +56) containing wild-type (30As) or truncated DATE (26As, 27As, 28A, 29As) from breast cancer
More informationPhenomena first observed in petunia
Vectors for RNAi Phenomena first observed in petunia Attempted to overexpress chalone synthase (anthrocyanin pigment gene) in petunia. (trying to darken flower color) Caused the loss of pigment. Bill Douherty
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More information2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria.
2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria October 8, 2013 Acute Intermittent Porphyria (AIP) Program Unmet Need and
More informationExpanding its HDL strategy into Immuno-oncology and Chemotherapeutic drug delivery. Acquisition of LYPRO Biosciences
Expanding its HDL strategy into Immuno-oncology and Chemotherapeutic drug delivery Acquisition of LYPRO Biosciences CERENIS is well positioned to change the drug delivery paradigm Over a decade of experience
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationSUPPLEMENTAL INFORMATION
SUPPLEMENTAL INFORMATION EXPERIMENTAL PROCEDURES Tryptic digestion protection experiments - PCSK9 with Ab-3D5 (1:1 molar ratio) in 50 mm Tris, ph 8.0, 150 mm NaCl was incubated overnight at 4 o C. The
More informationAuthors Rahul K. Keswani, Mihael Lazebnik & Daniel W. Pack
Reinstatement of Retroviral Infectivity via Non-Covalent Attachment of DOTAP, DOPE and Cholesterol to Murine Leukemia Virus-Like Particles Hybrid Viral/Lipid Gene Delivery Vectors Authors Rahul K. Keswani,
More informationImpact of a 1- or 2-dose starting regimen of inclisiran, a novel sirna inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year
ORION-1 Impact of a 1- or 2-dose starting regimen of inclisiran, a novel sirna inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend,
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationConference Call to Discuss FDA Approval of ONPATTRO (patisiran)
Conference Call to Discuss FDA Approval of ONPATTRO (patisiran) August 10, 2018 1 Agenda Welcome Christine Lindenboom Vice President, Investor Relations & Corporate Communications Introduction John Maraganore,
More informationArming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)
Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationNEOD001 for amyloid light-chain (AL) amyloidosis
NIHR Innovation Observatory Evidence Briefing: October 2017 NEOD001 for amyloid light-chain (AL) amyloidosis NIHRIO (HSRIC) ID: 10617 NICE ID: 8803 LAY SUMMARY Amyloid light-chain (AL) amyloidosis is caused
More information2011 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. December 12, 2011
211 ASH Annual Meeting Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia December 12, 211 Hepcidin is Central Regulator of Iron Homeostasis Hepcidin is liver-expressed,
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationSupplemental Material:
Supplemental Material: MATERIALS AND METHODS RNA interference Mouse CHOP sirna (ON-TARGETplus SMARTpool Cat# L-062068-00) and control sirna (ON-TARGETplus Control) were purchased from Dharmacon. Transfection
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationRobert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver
Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator: ODYSSEY Outcomes Study (Phase III Sanofi) Speakers Bureau: Sanofi, Regeneron Case Report
More informationDelivery of proteins (Routes of administration and absorption enhancement) The parenteral route of administration:
Delivery of proteins (Routes of administration and absorption enhancement) 1 The parenteral route of administration: Parenteral administration is here defined as administration via those routes where a
More informationAlnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis
FREE Screening Program* Alnylam Assist: Screening for Familial Amyloidotic Polyneuropathy (FAP) in TTR Amyloidosis Alnylam Pharmaceuticals, Inc. is committed to advancing the diagnosis and treatment of
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More information2.5. AMPK activity
Supplement Fig. A 3 B phos-ampk 2.5 * Control AICAR AMPK AMPK activity (Absorbance at 45 nm) 2.5.5 Control AICAR Supplement Fig. Effects of AICAR on AMPK activation in macrophages. J774. macrophages were
More informationKevin Fitzgerald, PhD
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results Kevin Fitzgerald, PhD Co-authors: Amy
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationAllosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor!
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor Allosteric pocket SHP2 Phosphatase ovel allosteric Phosphatase inhibitor Evan Carder Wipf
More informationSummary of plenary sessions on October 31, 2015
4 th ATTR/Familial Amyloidosis Support Meeting October 31 to November 1, 2015 Hilton Chicago O Hare Airport hotel Summary of plenary sessions on October 31, 2015 1 Contents Welcome... 3 Why are we here?
More informationPCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,
More informationEarly Clinical Development #1 REGN727: anti-pcsk9
Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationDevelopment of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia
Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia November 12 th, 2018 So C. Wong Arrowhead Pharmaceuticals Inc. Disclosures All authors
More information